# OnCo record waldenstrom (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/waldenstrom/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "waldenstrom" ;
  schema:name "Waldenström macroglobulinaemia"@en ;
  schema:alternateName "Lymphoplasmacytic lymphoma"@en, "WM"@en ;
  schema:description "A slow lymphoma that makes an abnormal IgM antibody, causing thick blood, anaemia and nerve damage. Nearly all cases share one mutation (MYD88 L265P), and BTK inhibitors control it for years."@en ;
  schema:url <https://onco.cc/cancers/waldenstrom/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Waldenstr%C3%B6m_macroglobulinemia> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1778287> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1475>, <https://iwmf.com/>, <https://doi.org/10.1182/blood.2020006844> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cxcr4/>, <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/mavorixafor/> ;
  onco:companies <https://onco.cc/companies/beone/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/ighv-status/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/myd88-l265p/>, <https://onco.cc/terms/m-protein-free-light-chains/> ;
  onco:trials <https://onco.cc/trials/aspen-wm/> ;
  onco:people <https://onco.cc/people/meletios-dimopoulos/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tam-blood/> ;
  onco:pipeline <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/zanubrutinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> .